Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anika Therapeutics, Inc.ANIK · Entity 6005 | Director | August 03, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anika Therapeutics, Inc.
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,015 |
Ending reported balance
After 2026-08-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-03 · Purchase · Acquired 1,000 · Balance 53,015 Row 2 · 2026-08-04 · Purchase · Acquired 1,000 · Balance 54,015 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Conformis Inc
Report date September 05, 2023 · Filed September 05, 2023
Section 16 reporting ended · disclosed 2023-09-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-05 transaction · row 1
1 source rowRow 1 · 2023-09-05 · Disposition to issuer · Disposed 10,470 · Balance 0 F1: The reported securities were disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 22, 2023, by and among Issuer, restor3d, Inc., a Delaware corporation ("restor3d"), and Cona Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of restor3d ("Merger Sub"). Immediately prior to effectiveness of the merger, each outstanding share of restricted stock vested in full. Upon effectiveness of the merger, in exchange for each share of Common Stock, the reporting person received $2.27 in cash, without interest and less applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 22, 2023, by and among Issuer, restor3d, Inc., a Delaware corporation ("restor3d"), and Cona Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of restor3d ("Merger Sub"). Immediately prior to effectiveness of the merger, each outstanding share of restricted stock vested in full. Upon effectiveness of the merger, in exchange for each share of Common Stock, the reporting person received $2.27 in cash, without interest and less applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 04, 2026 Filed Aug 5, 2026 20:30 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | PurchaseCommon Stock | 1,000 | $20.32 | $20,315.00 |
DisclosureSEC source: 0001193125-26-335269 · ownership.xml · nonDerivative · entry 2 Fischetti Gary P · CIK 0001929510 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,015 Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 20:30 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | PurchaseCommon Stock | 1,000 | $20.75 | $20,745.00 |
DisclosureSEC source: 0001193125-26-335269 · ownership.xml · nonDerivative · entry 1 Fischetti Gary P · CIK 0001929510 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,015 Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 20:30 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 10,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-279545 · ownership.xml · nonDerivative · entry 1 Fischetti Gary P · CIK 0001929510 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,015 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 21:06 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 14,164 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-004065 · ownership.xml · nonDerivative · entry 1 Fischetti Gary P · CIK 0001929510 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,613 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 20:32 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 5,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-003905 · ownership.xml · nonDerivative · entry 1 Fischetti Gary P · CIK 0001929510 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,449 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2025 annual meeting of the Company's stockholders or July 9, 2025. Read SEC document |
| September 05, 2023 Filed Sep 5, 2023 10:13 UTC | Conformis Inc CFMS · Entity 109987 | Disposition to issuerCommon Stock | 10,470 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-042503 · form4.xml · nonDerivative · entry 1 Fischetti Gary P · CIK 0001929510 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The reported securities were disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 22, 2023, by and among Issuer, restor3d, Inc., a Delaware corporation ("restor3d"), and Cona Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of restor3d ("Merger Sub"). Immediately prior to effectiveness of the merger, each outstanding share of restricted stock vested in full. Upon effectiveness of the merger, in exchange for each share of Common Stock, the reporting person received $2.27 in cash, without interest and less applicable withholding taxes. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:16 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-003958 · ownership.xml · nonDerivative · entry 1 Fischetti Gary P · CIK 0001929510 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,678 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2024 annual meeting of the Company's stockholders or June 14, 2024. Read SEC document |
| April 13, 2023 Filed Apr 17, 2023 20:32 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 12,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-002340 · ownership.xml · nonDerivative · entry 1 Fischetti Gary P · CIK 0001929510 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,178 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning on April 13, 2024. Read SEC document |
| May 24, 2022 Filed May 26, 2022 16:40 UTC | Conformis Inc CFMS · Entity 109987 | GrantCommon Stock | 261,740 | $0.00 | $0.00 |
DisclosureSEC source: 0001305773-22-000066 · wf-form4_165358324293433.xml · nonDerivative · entry 1 Fishetti Gary P · CIK 0001929510 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,740 F1 · shares: Represents initial equity grant for Reporting Person in connection with his appointment as a Board of Director. The awards vest over three years, with the following schedule: 33%, 33% and 34% of the total number of shares vesting on each one-year anniversary of the grant date, subject to Reporting Person's continued service as an employee of Conformis through the applicable vesting dates, and are subject to certain forfeiture provisions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.